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Abstract
Introduction: Progression-free survival (PFS) and overall survival (OS) endpoints often only weakly correlate. This
analysis investigates how different progression events impact on OS, using data from two phase 3 studies with
eribulin in women with advanced/metastatic breast cancer (MBC).
Methods: In Study 301, 1102 women with ≤2 prior chemotherapies for advanced/MBC were randomized to eribulin
mesylate (1.4 mg/m2 on days 1 and 8 every 21 days) or capecitabine (1.25 g/m2 twice daily on days 1–14 every
21 days). Study 305/EMBRACE enrolled 762 patients following two to five prior chemotherapies for advanced/MBC,
randomized to eribulin (as above) or treatment of physician’s choice. We analyzed OS and PFS post hoc for patients
whose disease progressed due to development of “new” metastases, growth of pre-existing lesions, and patients with
no reported disease progression.
Results: In both clinical studies, development of new metastases was associated with an increased risk of death
(p < 0.0001). The time to development of new metastasis or death was significantly longer with eribulin than
the comparator in Study 305 (p = 0.0017), but not in Study 301 (p = 0.46). Significantly longer OS was observed
in the eribulin compared with the comparator arm for the new metastases subgroup in Study 301 (p = 0.008),
but not in Study 305 (p = 0.16), compared with other progression subgroups.
Conclusions: Patients with MBC progressing with new metastases have a worse prognosis than those whose disease
progresses due to growth of existing lesions or patients with no reported disease progression. These findings have
potentially important implications for the interpretation of clinical study data and clinical practice.
Trial registration: ClinicalTrials.gov registration IDs: Study 301: NCT00337103; Study 305: NCT00388726.
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Introduction
Overall survival (OS) has been regarded as the gold-
standard endpoint in phase 3 cancer studies since the
1980s when it replaced objective response rate (ORR) as
the principal endpoint for studies supporting anticancer
drug approval [1, 2]. OS benefits can, however, be difficult
to assess because they may require a large patient popula-
tion and a prolonged follow-up period to demonstrate a
statistically significant difference [3, 4]. Additionally, in
clinical studies evaluating therapy earlier in the course of
metastatic disease, OS may be strongly influenced by subse-
quent lines of therapy [5, 6]. Many phase 3 oncology stud-
ies, including those in metastatic breast cancer (MBC),
have therefore used alternative primary endpoints (also
known as intermediate endpoints) such as progression-free
survival (PFS) [3]. Use of PFS markedly reduces the number
of patients necessary to establish a statistically significant
benefit, particularly when the time between the progression
event and death may be relatively long [4] or when there is
extensive crossover [7].
Despite widespread use in clinical trials, many inter-
mediate endpoints are poorly defined or have varying
definitions in the literature, making it difficult to consist-
ently interpret treatment effects and reliably perform
cross-trial comparisons. The heterogeneity of definitions
for endpoints has triggered the recent DATECAN
(Definition for the Assessment of Time-to-Event End-
points in CANcer trials) initiative, aimed at standardiz-
ing consensus definitions of endpoints for multiple
cancer sites, including breast cancer [8].
Meta-analyses of intermediate endpoints, such as PFS,
have suggested that these are often not reliable surrogate
endpoints for OS in MBC [3]. A recent United States
Food and Drug Administration evaluation of 12 clinical
studies submitted in support of approvals for treatments
for MBC suggested that PFS and OS are only weakly
correlated (R2 = 0.079) [9]. This poor correlation may be
due, at least in part, to crossover and variations in
poststudy anticancer therapies [7].
It can, therefore, be difficult to interpret the true
clinical impact of a new agent that improves PFS but not
OS, particularly when other treatments with established
OS benefits are available [10]. Thus, there is an ongoing
debate as to whether benefits in PFS, in the absence of
increases in OS, are clinically relevant [11]. By contrast,
while less common historically, increases in OS without
improvements in PFS have been reported in phase 2 and
3 studies of immunotherapies [12, 13] and with an
endothelin receptor antagonist [14, 15] in patients with
castration-resistant metastatic prostate cancer, as well as in
a phase 3 study comparing antiepidermal growth factor
receptor and antivascular endothelial growth factor therap-
ies for metastatic colorectal cancer [16]. Further, it is
increasingly questioned whether PFS, as conventionally
defined, is a meaningful endpoint in clinical studies of
immunotherapies, where a tumor "flare—characterized by
active inflammation, enhancement and even potentially in-
creased tumor mass— may be seen before a conventional
response has had time to develop [17–19].
Improvements in OS, but not PFS, have been observed
in only a few clinical studies of cytotoxic chemotherapy
[20–22]. In two recent, large-scale, randomized, phase 3
clinical studies of the nontaxane microtubule dynamics
inhibitor eribulin, patients in the eribulin arm appeared
to benefit more in terms of OS than PFS [23, 24]. One
of these studies (Study 305/Eisai Metastatic Breast
Cancer Study Assessing Physician’s Choice Versus E7389
[EMBRACE]) [23] demonstrated a significant increase in
the primary endpoint of OS with eribulin compared with
treatment of physician’s choice (TPC) in women with
MBC who had received between two to five previous
chemotherapy regimens, including ≥2 for advanced
disease (median 13.1 vs. 10.6 months; hazard ratio [HR]
0.81; 95 % confidence interval [CI] 0.66, 0.99; p = 0.041).
There was a small but significant difference in favor of
eribulin in PFS as assessed by investigator (HR 0.76;
95 % CI 0.64, 0.90; p = 0.002), but not independent
review (HR 0.87; 95 % CI 0.71, 1.05; p = 0.137), likely
due to fewer patients being censored with investigator
review, resulting in more progression events, compared
with independent review. The median PFS values were,
however, similar for the independent and investigator
reviews [23].
A separate clinical study (Study 301) compared eribulin
with capecitabine in patients with MBC who had received
up to three prior chemotherapy regimens, including ≤2 for
advanced or metastatic disease [24]. This study showed a
numerical difference favoring improved OS with eribulin
compared with capecitabine; although this difference was
not statistically significant (median 15.9 vs. 14.5 months;
HR 0.88; 95 % CI 0.77, 1.00; p = 0.056). PFS was almost
identical in both treatment arms (median 4.1 vs. 4.2 months;
HR 1.08; 95 % CI 0.93, 1.25; p = 0.30) [24]. Sensitivity
analyses adjusting for a crossover effect and postprogres-
sion anticancer treatments were consistent with the
primary analysis [25], suggesting that neither of these
fully explain the apparent discordance between OS
and PFS.
In response to the challenges of interpreting PFS or
disease-free survival (DFS) data, the European Medicines
Agency (EMA) recently published guidelines for consider-
ation when using these endpoints in clinical studies [26].
PFS is a composite endpoint, including the appearance of
“new” lesions (i.e., newly detected metastases, in a new or
pre-existing metastatic site), progression of existing metas-
tases (i.e., those present at baseline), mixed responses with
some lesions increasing in size but others decreasing in size,
and death. The EMA guidelines recommend the use of
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separate analyses that disassemble PFS into specific
progression events. Accordingly, we have performed
post hoc analyses of data from Study 301 and Study
305/EMBRACE to assess whether the study drugs had
different effects on OS according to the type of pro-
gression event, and to explore the apparent discord-
ance between OS and PFS.
Our first aim was to investigate whether the type of
progression event was predictive for OS in Study 301
and Study 305/EMBRACE. In addition, we investigated
whether a modified PFS, “new-metastasis–free survival,”
defined as the time from randomization to progression
due to a “new” metastasis or death, renders better con-
cordance with OS between the eribulin and control
(TPC or capecitabine) arms.
Methods
The clinical study design and efficacy and safety results of
Study 301 [24] and Study 305/EMBRACE [23] have been
reported elsewhere. Key eligibility criteria and treatment
details are summarized briefly here. All patients gave writ-
ten, informed consent. Approval was obtained from inde-
pendent ethics committees and regulatory authorities in
participating countries (Appendix I). The studies were con-
ducted in accordance with the World Medical Association
(WMA) Declaration of Helsinki (WMA General Assembly,
Tokyo, 2004) guidelines of the Committee for Proprietary
Medicinal Products/International Conference for Harmon-
isation/Good Clinical Practice (CPMP/ICH/135/95), and
local ethical and legal requirements.
Clinical study designs
Study 301 [24]
Patients who had received up to three prior chemotherapy
regimens, including up to two regimens for advanced and/
or metastatic disease, were eligible; prior therapy must have
included an anthracycline and a taxane. Eligible patients
were randomized 1:1 to 1.4 mg/m2 eribulin mesylate
intravenously (equivalent to 1.23 mg/m2 eribulin [as
free base]) on days 1 and 8 of a 21-day cycle, or capecit-
abine 1.25 g/m2 orally twice daily on days 1–14 of a 21-
day cycle. Patients were stratified by geographic region
and human epidermal growth factor receptor 2 status.
Study 305/EMBRACE [23]
Patients were required to have received two to five
previous chemotherapy regimens, including an anthracy-
cline and a taxane, with at least two regimens for locally
recurrent breast cancer or MBC. Eligible patients were
randomized 2:1 to eribulin (using the same dose and
schedule as in Study 301) or TPC, defined as: any single-
agent chemotherapy, hormonal, or biological treatment
approved for the treatment of cancer; radiotherapy; or
symptomatic treatment alone. Patients were stratified by
geographical region, previous capecitabine use, and
human epidermal growth factor receptor 2 status.
Post hoc analysis of PFS and OS
Progression events (determined using Response Evaluation
Criteria In Solid Tumors [RECIST] version 1.0) [27] from
both clinical studies were categorized as: detection of a new
lesion/metastasis (defined as a lesion not identified at base-
line); increase in the sum of the longest diameters of pre-
existing target lesions (i.e., those present at baseline) or an
increase in the size of at least one nontarget lesion reported
at baseline; and patients with no reported disease progres-
sion that includes death, clinical deterioration, and patients
who were censored. If progressive disease was detected
objectively (radiologically or by objective clinical measure-
ment of skin lesions), patients in whom a new lesion was
detected were classified as such, even if there was also
progression of existing lesions. Based on the above classifi-
cation, new-metastasis–free survival, defined as the time
from randomization to death or progression due to a new
metastasis (whichever occurred earlier), was used to investi-
gate the treatment effect in the progression type of special
interest, and to better understand the potential relationship
between disease progression and OS. The time to new
metastasis in vital organs (central nervous system [CNS],
lungs, or liver) was also calculated because we hypothe-
sized that such metastases may have a particular impact
on outcomes.
Independent review of disease progression in the
intent-to-treat (ITT) population was used for the pri-
mary analyses. Separate analyses were conducted with
investigator review (data not shown); however, results by
independent review only are presented here because they
are considered to be more reliable. Moreover, because PFS
from independent reviews showed discordance with OS in
both studies, it is further appropriate to explore the reasons
of such discordance using the independent review data.
Statistical analyses
The correlation between progression events and OS was
investigated by Cox regression, incorporating the devel-
opment of a new lesion/metastasis as a time-dependent
covariate. OS in the different treatment groups was
compared by PFS status using Cox regression and strati-
fied log-rank tests. In the analysis of new-metastasis–
free survival, the cumulative incidence competing risk
(CICR) method [28] was used to estimate the cumulative
probabilities of disease progression due to the development
of a new lesion or death, in which progression due to exist-
ing lesion was considered as a competing risk. The CICR
method (unlike the Kaplan-Meier estimator) does not
require any assumption about independence of the compet-
ing risks. The independence assumption required by log-
rank test implies that at each time point the hazard of
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developing new metastases or death is the same for patients
who were in follow-up and had no event, and for patients
who died due to growth of a pre-existing lesion by that
time, which cannot be verified in our studies. The unstrati-
fied Gray’s test [29] was used to compare the cumulative
incidence functions between the two treatment arms in the
competing risks setting. Because death or progression due
to an existing lesion or nonvital new lesion was censored
by definition in the calculation of time to new metastasis in
vital organs (i.e., competing risks are not considered),
Kaplan-Meier estimator and log-rank tests were used to
estimate the treatment difference.
Results
Study 301 comprised 1102 patients in the ITT population,
with 554 in the eribulin arm and 548 in the capecitabine
arm. Study 305/EMBRACE comprised 762 patients in the
ITT population, with 508 in the eribulin arm and 254 in
the TPC arm. Consolidated Standards of Reporting Trials
(CONSORT) diagrams for both clinical studies have been
published previously [23, 24]. The results described below
are based on tumor assessment by independent review;
however, similar results were obtained with investigator
review (data not shown), unless stated otherwise.
Study 301
Prognostic effects of type of progression
Of the 1102 patients in the ITT population, 1101 had
baseline scans, and 420 (38.1 %) patients had disease
progression due to the development of new metastases.
Patients who were deemed to have tumor progression
due to new metastases had an increased risk of death
compared with all other patients (n = 682; median OS
13.0 months vs. 17.1 months, respectively), regardless of
whether the data were stratified by treatment group or
not (HR 1.98 and 1.96; p < 0.0001; Tables 1 and 2).
Similar findings were observed when median OS was
compared between patients whose disease progressed due
to new metastases and those whose disease progressed spe-
cifically due to an increase in the size of pre-existing lesions
(n = 420 vs. 243, respectively; 13.0 months vs. 17.1 months,
respectively), regardless of stratification (HR 1.81 and 1.80;
p < 0.0001; Tables 1 and 2). Median OS was also shorter for
patients who developed new metastases than for those
patients with no reported disease progression (which in-
cludes death, clinical deterioration and censoring; [n = 439],
13.0 months vs. 16.9 months, respectively) irrespective of
stratification (HR 2.20 and 2.16, p < 0.0001; Tables 1 and 2).
Comparison of eribulin versus capecitabine according to
progression event
Disease progression due to new metastases occurred in 216
patients (39.0 %) in the eribulin arm compared with 204
patients (37.2 %) in the capecitabine arm. In the eribulin
arm, 131 patients (23.7 %) progressed due to an increase in
the size of pre-existing lesions, compared with 112 (20.4 %)
in the capecitabine arm. Two hundred seven (37.4 %) pa-
tients in the eribulin arm, which represented 148 (26.7 %)
deaths, and 232 (42.3 %) patients in the capecitabine arm,
which represented 179 (32.7 %) deaths, were associated
with no reported disease progression.
Median OS for patients whose disease progressed due to
new metastases was significantly longer with eribulin than
with capecitabine (14.6 vs. 11.3 months; HR 0.75; p = 0.008;
Table 2). For those whose disease progressed due to an
increase in the size of pre-existing lesions, median OS was
18.0 versus 16.7 months (HR 0.92; p = 0.57; Table 2). In
patients with no reported disease progression, median OS
was 17.6 versus 16.8 months (HR 0.91; p = 0.44) for eribulin
and capecitabine, respectively.
Cumulative probabilities of new metastasis or death
were similar in both arms (Gray’s test p = 0.46; Fig. 1a).
Sensitivity analysis of new-metastasis–free survival using
log-rank test showed similar results (median 5.8 vs.
5.8 months; HR 1.00; p = 0.99; Fig. 2a). For patients
whose disease progressed due to new metastases, there
were no notable differences in the incidence of new
metastases in different organs (Table 3). In addition, the
time to new metastases in patients whose disease pro-
gressed due to new metastases in vital organs (CNS, lungs,
or liver) was also not significantly different between the
two treatment arms (HR 0.81; p = 0.12; Fig. 3a).
Comparison of eribulin versus capecitabine according to
treatment duration
No significant differences in treatment duration were
observed between the patients treated with eribulin versus
capecitabine irrespective of the type of progression event
subgroup (p = ns for all; data not shown).
Study 305/EMBRACE
Prognostic effect of type of progression
The ITT population comprised 762 patients, of whom 760
had baseline scans and 207 (27.2 %) had disease progres-
sion due to new metastases. Similar to Study 301, patients
with tumor progression due to new metastases were at an
increased risk of death compared with all other patients
(n = 555), whether stratified by treatment group or not
(median OS 11.1 vs. 12.5 months, respectively; HR 2.25
and 2.27, respectively; p < 0.0001; Tables 1 and 4).
The same differences in median OS were also observed
for disease progression due to a new metastases compared
with progression specifically due to an increase in the size
of pre-existing lesions (n = 262; median OS 11.1 vs.
12.2 months, respectively), whether stratified by treatment
group or not (HR 2.09 and 2.12, respectively; p < 0.0001;
Tables 1 and 4). Patients in the new metastases subgroup
also had an increased risk of death compared with the
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patients with no reported disease progression (that
includes death, clinical deterioration, and censoring),
([n = 293]; 11.1 vs. 13.0 months, respectively) irrespect-
ive of stratification (HR 2.61 and 2.60; p < 0.0001;
Tables 1 and 4).
Comparison of eribulin versus TPC according to progression
event
Disease progression due to new metastases occurred in
139 patients (27.4 %) in the eribulin arm and 68 patients
(26.8 %) in the TPC arm; an increase in the size of pre-
existing lesions occurred in 189 (37.2 %) and 73 (28.73 %)
patients receiving eribulin and TPC, respectively. In the
eribulin arm, there were 180 (35.4 %) patients with no
reported disease progression, compared with 113 (44.5 %)
patients in the TPC arm which comprised 85 (16.7 %) and
61 (24.0 %) deaths in the eribulin and TPC arms,
respectively. The proportion of patients whose disease
progressed due to new metastases was lower in Study
305/EMBRACE than in Study 301 (27.2 % vs. 38.1 %).
Median OS in the eribulin arm was not statistically differ-
ent from that in the TPC arm for patients whose disease
progressed due to new metastases (12.3 vs. 8.4 months; HR
0.76; p = 0.16; Table 4), for those whose disease progressed
due to an increase in the size of pre-existing lesions (13.0
vs. 11.1 months; HR 0.74; p = 0.14; Table 4) or those with
no reported disease progression (15.8 vs. 10.7 months; HR
0.77; p = 0.16; Table 4). Although, in the investigator review
analysis, the difference in median OS with eribulin com-
pared with the TPC arm in patients with no reported
disease progression reached statistical significance (16.1 vs.
9.9 months; HR 0.66; p = 0.03).
New-metastasis–free survival was longer in the eribulin
arm compared with the TPC arm, as indicated by the
lower cumulative incidence rate curve of the eribulin arm
(Fig. 1b). The differences in cumulative functions between
the two arms were statistically significant (Gray’s test, p =
Table 1 Disease progression due to new metastasis as a risk factor of overall survival (intent-to-treat population)
Study 301 Study 305/EMBRACE
Stratified by treatment group Not stratified Stratified by treatment group Not stratified
Compared with all othera subjects
Patients, n 1102 762
HR (95 % CI) 1.98 (1.71, 2.29) 1.96 (1.70, 2.27) 2.25 (1.79, 2.83) 2.27 (1.80, 2.85)
Wald p value <0.0001 <0.0001 <0.0001 <0.0001
Compared with those whose disease progressed due to an increase in the size of pre-existing lesion(s)
Patients, n 663 469
HR (95 % CI) 1.81 (1.54, 2.14) 1.80 (1.53, 2.13) 2.09 (1.63, 2.68) 2.12 (1.65, 2.72)
Wald p value <0.0001 <0.0001 <0.0001 <0.0001
Compared with those with no reported disease progressionb
Patients, n 859 500
HR (95 % CI) 2.20 (1.88, 2.57) 2.16 (1.85, 2.53) 2.61 (2.03, 3.37) 2.60 (2.02, 3.34)
Wald p value <0.0001 <0.0001 <0.0001 <0.0001
Tumor progression due to new metastasis is fitted as a time-dependent variable in the Cox regression model
CI confidence interval, EMBRACE Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389, HR hazard ratio
ai.e., progression due to growth of pre-existing lesion(s), or those with no reported disease progression (including death, clinical deterioration or censoring)
bPatients with no reported disease progression included death, clinical deterioration, or censoring
Table 2 Overall survival for different patient groups in Study 301
Progression due to new metastases Progression due to pre-existing lesions No reported disease progression
Eribulin Capecitabine Total Eribulin Capecitabine Total Eribulin Capecitabine Total






























p value 0.008 – 0.57 – 0.44 –
Progression events were determined by independent review
CI confidence interval, HR hazard ratio, OS overall survival
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0.0017). Sensitivity analysis of new-metastasis–free survival
using log-rank test showed similar results (median 6.4 vs.
4.8months; HR 0.70; p = 0.006; Fig. 2b).
There were again some differences in the sites of
new metastases between the eribulin and TPC arms
(Table 3), but these were modest and not consistent
with Study 301, with the exception of patients in the
eribulin arm appearing more likely to develop lymph
node, breast, and chest wall metastases, and patients
in the comparator arm appearing more likely to
develop liver and “other” metastases in both Study
305/EMBRACE and Study 301. The time to new
metastases in vital organs favored eribulin over TPC
(HR 0.63; p = 0.04; Fig. 3b).
Comparison of eribulin versus TPC according to treatment
duration
The patients whose disease progressed due to the develop-
ment of a new metastasis were treated with eribulin for a
significantly longer duration than those receiving capecita-
bine (median 139 vs. 68 days; p < 0.001). Similar results
were also observed in the subgroups of eribulin and cape-
citabine patients whose disease progressed due to an
EMBRACE; Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389; 
TPC, treatment of physician’s choice.
Fig. 1 Cumulative incidence function of new metastasis or death in studies (a) 301, and (b) 305/EMBRACE. The data are based on independent
review of the intent-to-treat population.
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CI, confidence interval; EMBRACE; Eisai Metastatic Breast Cancer Study Assessing  
Physician’s Choice Versus E7389; OS, overall survival; TPC, treatment of physician’s choice. 
Fig. 2 New-metasasis–free survival in studies (a) 301 and (b) 305/EMBRACE. The data are based on independent review of the intent-to-treat
population. New-metastasis–free survival was defined as the time from randomization to death or disease progression due to a new metastasis
(whichever occurred earlier).
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existing lesion (median: 189 vs. 73 days, respectively; p <
0.01) and in those with no reported disease progression
(median 174 vs. 107 days, respectively; p < 0.01).
Discussion
This analysis is, to our knowledge, the first to focus specif-
ically on new metastases as the cause of disease progres-
sion and to demonstrate that patients whose disease
progresses due to the development of new metastases have
worse OS time than those whose disease progresses due to
growth of pre-existing metastases and in comparison with
patients with no reported disease progression (the latter in-
cludes patients who died for reasons other than the devel-
opment of new metastasis or growth of pre-existing
lesions, patients who experienced clinical deterioration and
those that were censored). This confirms the clinical im-
pression that patients who develop new metastasis may have
a worse prognosis. Current RECISTcriteria do not, however,
distinguish between the different progression events.
Only a limited number of published clinical studies
have described how different progression events affect
OS, and their findings have varied. A post hoc analysis
of progression events in 246 patients with metastatic
renal cell cancer treated with everolimus in the REnal
Cell cancer treatment with Oral RAD001 given Daily
(RECORD-1) clinical study showed that the development
of new lesions and growth of nontarget lesions were both
predictive of worse OS (p < 0.001) in univariate analyses
[30]. In a multivariate analysis, nontarget progression
retained statistical significance (p = 0.005), but new meta-
static lesions had only borderline significance (p = 0.053)
[30]. In a metastatic colorectal cancer clinical study, the
appearance of new lesions or unequivocal progression of
nonmeasurable lesions both carried a worse prognosis (re-
garding survival) than other measures of progression; this
analysis was, however, restricted to assessment of the first
on-study response assessment [31]. The impact of differ-
ent time-dependent measures of response on OS was
recently described in a series of breast, lung, and colorec-
tal cancer studies [32]. In these analyses, worse OS was
significantly associated both with the development of new
metastatic lesions (p < 0.001) and progression of nontarget
lesions (p < 0.001).
In contrast, a preliminary report from the phase 3 Inter-
group study N9741 in 726 patients with advanced colorec-
tal cancer whose disease progressed on chemotherapy
found that individuals whose disease progressed due to
the development of new metastases had similar median
OS outcome as patients whose disease progressed in pre-
existing lesions [33].
Our analyses demonstrate that progression due to new
metastases is, indeed, associated with significantly worse
OS in patients with pretreated MBC. This finding has
important potential implications. In the context of clinical
studies, it is possible that one type of progression event
may be more predictive of OS than other types of progres-
sion events. The difference in prognosis, according to the
type of progression, might also reflect eligibility criteria: if,
for example, the desire is to select patients with a better
prognosis, those progressing with new metastases might
be excluded. In clinical practice, these data may also help
to inform oncologists and their patients when discussing
future treatment options and prognosis.
Our second objective was to investigate whether the
different types of progression explain the greater impact
of eribulin on OS than on PFS. “New-metastasis–free
Table 3 Summary of new metastases by sitea based on independent review (intent-to-treat populations)
Parameter Study 301 Study 305/EMBRACE
Eribulin Capecitabine Eribulin TPC
(n = 554) (n = 548) (n = 508) (n = 254)
Patients whose disease progressed owing to new metastases, n (%) 216 (39.0 %) 204 (37.2 %) 139 (27.4 %) 68 (26.8 %)
Sites of new metastasesb, n (%)
Liver 72 (33.3) 80 (39.2) 41 (29.5) 30 (44.1)
Lung 30 (13.9) 33 (16.2) 8 (5.8) 4 (5.9)
Lymph nodes 7 (3.2) 3 (1.5) 16 (11.5) 6 (8.8)
Bone 19 (8.8) 16 (7.8) 7 (5.0) 2 (2.9)
Skin 66 (30.6) 62 (30.4) 3 (2.2) 1 (1.5)
CNS (brain/spine) 4 (1.9) 17 (8.3) 7 (5.0) 0
Breast 12 (5.6) 7 (3.4) 3 (2.2) 0
Chest wall 9 (4.2) 4 (2.0) 25 (18.0) 5 (7.4)
Other 6 (2.8) 13 (6.4) 5 (3.6) 4 (5.9)
CNS central nervous system, EMBRACE Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389, TPC treatment of physician’s choice
aOnly the first new metastasis observed is recorded. If there were multiple new metastases observed at the same time and all determined as earliest, all new
metastasis sites were summarized
bPercentages for metastasis sites are based on the number of patients in each study arm whose disease progressed owing to new metastases
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CI, confidence interval; EMBRACE; Eisai Metastatic Breast Cancer Study Assessing  
Physician’s Choice Versus E7389; NE, not evaluable; TPC, treatment of physician’s choice. 
Fig. 3 Time to new metastases in vital organs in studies (a) 301, and (b) 305/EMBRACE. The data are based on independent review of the intent-to-treat
population. Vital organs constitute the central nervous system, lungs, or liver.
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survival,” a modified PFS that treats death and new
metastases (i.e., the more aggressive type of progression) as
the event of interest and progression due to existing lesion
as a competing risk, was compared between eribulin and
the comparator arms. Using the CICR method, new-
metastasis–free survival was longer in the eribulin arm
than in the comparator arm for Study 305 but not in Study
301. The log-rank test for comparing hazards of new me-
tastases or death also resulted in a p value of 0.006 in
the sensitivity analysis for Study 305. Taken together,
our results suggest that the development of new metasta-
ses is a risk factor for worsening OS and that the lower in-
cidence rates of new metastasis/death in the eribulin arm
may explain, at least in part, the OS benefit associated
with eribulin in Study 305. Additionally, in Study 305, pa-
tients in the eribulin arm were treated for longer than
those in the TPC arm irrespective of the type of progres-
sion event, which may also have contributed to better OS.
Although in Study 301 there was no difference in the
new-metastasis–free survival between the treatment arms,
the different types of progression events may provide some
explanation for the OS differences observed between treat-
ment arms. The modest increase in OS with eribulin
compared with capecitabine in Study 301 was primarily
driven by a significant improvement in OS in the new
metastasis subgroup, whereas in Study 305 a similar but
nonsignificant increase in OS was observed in the eribulin
arm in all three “progression” subgroups. In both clinical
studies, the proportion of patients with no reported disease
progression was lower in the eribulin arm than in the
comparator arm (37.4 % vs. 42.3 % in Study 301, and
35.4 % vs. 44.5 % in Study 305).
Thus, new-metastasis–free survival alone cannot
account for the observed discordance between PFS and
OS; however, a possible explanation for it may be attrib-
uted to the recently identified effects of eribulin on the
tumor microenvironment. Recent data in human breast
cancer models indicate that eribulin may remodel the
tumor microenvironment and vasculature, which may im-
prove its antitumor activity and drug delivery compared
with other cytotoxic agents [34]. These changes may also
potentially impact on the effects of concomitant and/or
subsequent anticancer therapies; further studies may be
able to substantiate this hypothesis.
One limitation of our analysis of the impact of the
development of new metastases on OS is that it was post
hoc rather than preplanned. Further, this analysis was
not powered for the subgroups reviewed; subsequently,
no definitive conclusions can be drawn. These analyses
were, however, prompted by the EMA guidelines. It may
also be questioned whether our findings can be general-
ized to the broader population of patients with MBC.
Study 301 and Study 305/EMBRACE were, however,
both large well-designed phase 3 studies, with approxi-
mately a third (33.6 %) of the patients developing new
metastases and more than a quarter (27.1 %) experien-
cing progression due to growth of pre-existing lesions.
Further, although over half of patients (57.0 %) were
treated with a single cytotoxic agent (i.e., eribulin), the
remainder received a range of cytotoxic agents used to
treat MBC. Finally, our finding of the association between
the development of new metastases and worse OS was
consistent across both clinical studies. These retrospective
findings warrant further investigation in phase 3 MBC
datasets as well as prospective evaluation.
Conclusions
Patients with MBC who develop tumor progression with
new metastases have a worse prognosis than patients whose
disease progresses due to growth of pre-existing lesions and
compared with patients with no reported disease progres-
sion. This finding has potentially important implications
both for the interpretation of clinical study results, espe-
cially when PFS is the primary endpoint, and for clinical
practice. “New-metastasis–free survival” may be a useful
complement to PFS in understanding the dynamic between
disease progression and survival. The relationship between
the different progression events and OS warrants further
investigation.
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